Methods to determine the efficacy of adalimumab in subjects having ankylosing spondylitis using CTX-II and MMP3 as biomarkers

摘要

A method for determining the efficacy of adalimumab for the treatment of ankylosing spondylitis (AS) in a subject having EA said method comprising determining a level of post-treatment of C-telopeptide of type II collagen (CTX-II) and level of post-treatment of matrix metalloproteinase 3 (MMP-3) in one or several samples obtained from the subject has AD where a level of post-treatment lower CTX-II in the sample or samples for levels known pattern CTX-II based on one or more subjects having AD and a level of post-treatment lower MMP3 in the sample or samples with respect to known levels pattern MMP3 based on one or more subjects 10 having EA It indicates that adalimumab is effective for treating AD in the subject